Sitagliptin vs Drospirenone: side-by-side comparison
Sitagliptin (DPP-4 inhibitor) and Drospirenone (Progestogen with anti-mineralocorticoid and anti-androgen activity) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Sitagliptin | Drospirenone |
|---|---|---|
| Therapeutic class | DPP-4 inhibitor | Progestogen with anti-mineralocorticoid and anti-androgen activity |
| CAS | 486460-32-6 | 67392-87-4 |
| ATC | A10BH01 | G03AA12 |
| Molecular weight | 407.31 g/mol | 366.49 g/mol |
| Brands with this active ingredient | 1 | 2 |
What they share
Sitagliptin and Drospirenone share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Sitagliptin acts by a different mechanism than Drospirenone, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Sitagliptin: Sitagliptin hemmt reversibel DPP-4, die Serinprotease, die für den schnellen Abbau von Glucagon-like Peptid 1 (GLP-1) und glukoseabhängigem insulinotropen Polypeptid (GIP) verantwortlich ist. Drospirenone: Drospirenon aktiviert Progesteronrezeptoren, um die Ovulation zu unterdrücken und in Kombination mit einem Estrogen die kontrazeptive Wirkung zu erzielen.
Indications compared
Sitagliptin: Sitagliptin ist bei Erwachsenen mit Typ-2-Diabetes mellitus, allein oder in Kombination mit anderen antidiabetischen Wirkstoffen, zur Verbesserung der glykämischen Kontrolle zugelassen. Drospirenone: Drospirenon in Kombination mit Ethinylestradiol ist als kombinierte orale Kontrazeption, zur Behandlung mittelschwerer Akne bei Frauen, die eine Kontrazeption wünschen, und zur Behandlung der prämenstruellen dysphorische…
Safety profile
Sitagliptin: Sitagliptin wird im Allgemeinen gut vertragen. Drospirenone: Häufige Nebenwirkungen sind Menstruationsstörungen, Mammaspannen, Kopfschmerzen, Stimmungsänderungen und Übelkeit, meist in den ersten 2–3 Zyklen.
Häufig gestellte Fragen
Is Sitagliptin better than Drospirenone? ▾
Sitagliptin and Drospirenone are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Sitagliptin and Drospirenone be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Sitagliptin
Products with Drospirenone
Die Informationen auf dieser Website dienen ausschließlich zu Referenz- und Bildungszwecken. Sie ersetzen nicht die Beratung durch qualifiziertes medizinisches Fachpersonal.